Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Imatinib mesylate (IM) binds to the BCR-ABL protein, inhibiting its kinase activity and effectively controlling diseases driven by this kinase. IM resistance has been associated with kinase mutations or increased BCR-ABL expression. However, disease progression may be mediated by other mechanisms that render tumor cells independent of BCR-ABL. To demonstrate this potential, IM-resistant cells were found in chronic myelogenous leukemia patients with continuous BCR-ABL gene expression but undetectable BCR-ABL protein expression. These cells were unresponsive to IM and acquired BCR-ABL-independent signaling characteristics. IM resistance in some patients may be mediated through loss of kinase target dependence.

[1]  M. Neeman,et al.  Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. , 2003, Cancer research.

[2]  H. Kagan,et al.  Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell , 2003, Journal of cellular biochemistry.

[3]  Sujay K. Singh,et al.  Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis , 2003 .

[4]  D. Boschelli,et al.  SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. , 2003, Cancer research.

[5]  N. Donato,et al.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. , 2003, Blood.

[6]  M. Talpaz,et al.  Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients , 2002, Leukemia.

[7]  Matthew B. Wilson,et al.  Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr–Abl signal transduction and oncogenesis , 2002, Oncogene.

[8]  C. Eaves,et al.  Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. , 2002, Blood.

[9]  B. Druker,et al.  The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. , 2002, Blood.

[10]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[11]  Yu Shen,et al.  Myelodysplastic syndrome is not merely "preleukemia". , 2002, Blood.

[12]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[13]  Jiang Zhu,et al.  Hematopoietic cytokines, transcription factors and lineage commitment , 2002, Oncogene.

[14]  R. Herrmann,et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.

[15]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[16]  R. Jove,et al.  Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors , 2002, Leukemia.

[17]  B. Druker,et al.  Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.

[18]  Sujay K. Singh,et al.  Curcumin (Diferuloylmethane) Downregulates the Constitutive Activation of Nuclear Factor κB and IκBα Kinase in Human Multiple Myeloma Cells Leading to Suppression of Proliferation and Induction of Apoptosis , 2002 .

[19]  H. Nakshatri,et al.  Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor kappaB-mediated antiapoptosis involving c-IAP2. , 2001, Blood.

[20]  M. Karin,et al.  Signal transduction by tumor necrosis factor and its relatives. , 2001, Trends in cell biology.

[21]  N. Miyasaka,et al.  CrkL Is Recruited through Its SH2 Domain to the Erythropoietin Receptor and Plays a Role in Lyn-mediated Receptor Signaling* , 2001, The Journal of Biological Chemistry.

[22]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[23]  A. Glassman,et al.  Spectral karyotyping study of chromosome abnormalities in human leukemia. , 2001, Cancer genetics and cytogenetics.

[24]  H. Kantarjian,et al.  Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. , 2001, Blood.

[25]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[26]  C. Eaves,et al.  Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. , 2001, Blood.

[27]  K. Csiszȧr,et al.  Lysyl oxidases: a novel multifunctional amine oxidase family. , 2001, Progress in nucleic acid research and molecular biology.

[28]  H. Kagan,et al.  Biochemistry and Molecular Biology of Vitamin B6 and PQQ-dependent Proteins , 2000, Birkhäuser Basel.

[29]  J. Melo,et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.

[30]  Matthew B. Wilson,et al.  Transformation of Myeloid Leukemia Cells to Cytokine Independence by Bcr-Abl Is Suppressed by Kinase-defective Hck* , 2000, The Journal of Biological Chemistry.

[31]  J. Griffin,et al.  Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. , 2000, Blood.

[32]  E. Montserrat,et al.  Blast Crisis of Ph-Positive Chronic Myeloid Leukemia with Isochromosome 17q: Report of 12 Cases and Review of the Literature , 2000, Leukemia & lymphoma.

[33]  S. Fong,et al.  Lysyl oxidase: a family of multifunctional proteins , 2000 .

[34]  Z. Estrov,et al.  The biology of chronic myeloid leukemia. , 1999, The New England journal of medicine.

[35]  A. Kraker,et al.  Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth , 1999, Leukemia.

[36]  M. Gerritsen,et al.  Novel Inhibitors of Cytokine-induced IκBα Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in Vivo* , 1997, The Journal of Biological Chemistry.

[37]  M. Hung,et al.  Epidermal growth factor receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[38]  J. Okamura,et al.  Two bcr/abl fusion gene products, P210bcr/abl and P190bcr/abl, are equally sensitive to the protein tyrosine phosphatase of mature granulocytes. , 1991, International journal of hematology.

[39]  G. Jenster,et al.  Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.

[40]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[41]  R. Gale,et al.  Chronic myeloid leukemia. , 1992, The American journal of medicine.